- Adjuvant chemotherapy was associated with better OS and DFS in stage II obstructing colon cancer.
Why this matters
- The study is the first to examine the association between adjuvant chemotherapy and outcomes specifically in stage II obstructing colon cancer.
- Propensity-matched, retrospective, multicenter cohort study (n=504).
- The researchers used an Average Treatment effect on the Treated (ATT) analysis, where treated patients had a weight of 1 and untreated patients had weights corresponding to their probability of receiving treatment.
- Funding: None disclosed.
- 35.5% of patients underwent adjuvant chemotherapy.
- A multivariate analysis with ATT weighting and adjustment showed that treatment was associated with better OS (HR, 0.42; P=.0498) and better DFS (HR, 0.57; P=.0116).
- When the analysis was limited to oxaliplatin-based regimens, adjuvant treatment was associated with improved OS (HR, 0.28; P=.0267) and a trend towards better DFS (HR, 0.63; P=.1016).
- Retrospective analysis.
- No prestudy power calculation was performed.